OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic potential of neurotrophic factors in Alzheimer’s Disease
Ava Nasrolahi, Fatemeh Javaherforooshzadeh, Mohsen Jafarzadehgharehziaaddin, et al.
Molecular Biology Reports (2021) Vol. 49, Iss. 3, pp. 2345-2357
Closed Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Stress-Induced Depression and Alzheimer’s Disease: Focus on Astrocytes
О. В. Долотов, Л. С. Иноземцева, N. F. Myasoedov, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4999-4999
Open Access | Times Cited: 56

Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges
Constance Delaby, Christophe Hirtz, Sylvain Lehmann
Revue Neurologique (2022) Vol. 179, Iss. 3, pp. 161-172
Open Access | Times Cited: 32

Nanotechnology-based gene therapy as a credible tool in the treatment of Alzheimer’s disease
NigelH Greig, Aziz Unnisa, MohammadAmjad Kamal
Neural Regeneration Research (2023) Vol. 18, Iss. 10, pp. 2127-2127
Open Access | Times Cited: 15

Innovative Formulation Platform: Paving the Way for Superior Protein Therapeutics with Enhanced Efficacy and Broadened Applications
Zheng Cao, Chaoyong Liu, Jing Wen, et al.
Advanced Materials (2024) Vol. 36, Iss. 41
Open Access | Times Cited: 5

Neuroprotection in Glaucoma: Basic Aspects and Clinical Relevance
Che‐Yuan Kuo, Catherine Jui-Ling Liu
Journal of Personalized Medicine (2022) Vol. 12, Iss. 11, pp. 1884-1884
Open Access | Times Cited: 19

Decoding the Role of Neurotrophins in Glycogen Synthase Kinase 3-Beta Regulation in Alzheimer’s Disease
Shubham Nilkanth Rahmatkar, Damanpreet Singh
Molecular Neurobiology (2025)
Closed Access

Marine Natural Products from the Russian Pacific as Sources of Drugs for Neurodegenerative Diseases
Yu. S. Khotimchenko, Д. Н. Силачев, Vladimir L. Katanaev
Marine Drugs (2022) Vol. 20, Iss. 11, pp. 708-708
Open Access | Times Cited: 14

Role of nerve growth factor on cognitive impairment in patients with Alzheimer's disease carrying apolipoprotein E ε4
Mingyue He, Zhan Liu, Teng-hong Lian, et al.
CNS Neuroscience & Therapeutics (2023) Vol. 30, Iss. 6
Open Access | Times Cited: 8

Harnessing Passive Pulsatile Shear Stress for Alzheimer’s Disease Prevention and Intervention
José A. Adams, Arkady Uryash, José R. López
Journal of Alzheimer s Disease (2024) Vol. 98, Iss. 2, pp. 387-401
Open Access | Times Cited: 2

Amyloidogenesis and Neurotrophic Dysfunction in Alzheimer’s Disease: Do They have a Common Regulating Pathway?
Fengjuan Jiao, Dongjun Jiang, Yingshuai Li, et al.
Cells (2022) Vol. 11, Iss. 20, pp. 3201-3201
Open Access | Times Cited: 12

Amyloid β induces cardiac dysfunction and neuro-signaling impairment in the heart of an Alzheimer’s disease model
Andrea Elia, Rebecca Parodi‐Rullán, Rafael Vázquez‐Torres, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5

Fucoidans: Exploring its neuroprotective mechanisms and therapeutic applications in brain disorders
Patrícia Batista, Sara A. Cunha, Tânia Bragança Ribeiro, et al.
Trends in Food Science & Technology (2023) Vol. 143, pp. 104300-104300
Open Access | Times Cited: 5

Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease
Sherif M. Reda, Sharay E. Setti, Andrée‐Anne Berthiaume, et al.
Neurotherapeutics (2024) Vol. 21, Iss. 4, pp. e00350-e00350
Open Access | Times Cited: 1

Brain-Derived Neurotrophic Factor – The Protective Agent Against Neurological Disorders
Prathyusha Koyya, Ram Kumar Manthari, Santhi Latha Pandrangi
CNS & Neurological Disorders - Drug Targets (2023) Vol. 23, Iss. 3, pp. 353-366
Open Access | Times Cited: 3

The Cracked Potential of Boron-containing Compounds in Alzheimer’s Disease
Marvin A. Soriano‐Ursúa, Eunice D. Farfán‐García
Central Nervous System Agents in Medicinal Chemistry (2023) Vol. 23, Iss. 3, pp. 213-221
Closed Access | Times Cited: 2

Membrane Budding Inspired Biomimetic Nanocarrier Delivers Brain‐derived Neurotrophic Factor to Improve AD Cognition
Antian Wang, Jialin Huang, Minxiu Ji, et al.
Advanced Functional Materials (2024)
Closed Access

Different drugs used as therapeutic targets against AD till date
Manisha Nahar, Aamir Khan, Ravina Rai, et al.
Elsevier eBooks (2024), pp. 191-216
Closed Access

Glaucoma
Meghal Gagrani, Vikas Gulati, Deepta Ghate, et al.
NeuroImmune Pharmacology and Therapeutics (2024), pp. 527-547
Closed Access

Molecular Aspects of a Diet as a New Pathway in the Prevention and Treatment of Alzheimer’s Disease
Julia Doroszkiewicz, Jan Mroczko, Piotr Rutkowski, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10751-10751
Open Access | Times Cited: 1

BI-D1870 Causes the Rats’ Learning and Memory Acquisition Ability Impairment
Chaojie Zhang, Ke He, Caixia Li, et al.
Journal of Biosciences and Medicines (2023) Vol. 11, Iss. 01, pp. 82-97
Open Access

Role of nerve growth factor on cognitive impairment in Alzheimer's disease patients carrying apolipoprotein E ε4
Mingyue He, Teng-hong Lian, Peng Guo, et al.
Research Square (Research Square) (2023)
Open Access

Page 1 - Next Page

Scroll to top